Market research
CING Cingulate Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 21.2
- Dividend yield
- Not available
- Beta
- -0.89
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US17248W3034
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 21.2
- Dividend yield
- Not available
- Beta
- -0.89
About
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CING discussion.
No comments yet
Start a focused discussion about CING.